Sorrento’s Scilex Holding Company To Acquire Ancora Medical; Terms Not Disclosed
Ancora Medical Inc. ("Ancora") is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during
Inspira Technologies Signs Agreement With Glo-Med Networks To Potentially Provide $59M For Deployment Of 3,889 HYLA Blood Sensors
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, following
Dogness Announces Retail Distribution Partnership With Xiuhu
Dogness Continues to Build Momentum in its Largest Revenue Markets
DONGGUAN, China, July 7, 2022 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company")
Kiromic BioPharma Announces Completion Of Expanded cGMP Manufacturing Facility To Support Cell Therapy Oncology Pipeline
Construction Completion is One of the Pre-requisites to Beginning the Deltacel™ Clinical Trial Activation Later This Year and Addresses a Key Clinical Hold Citation
Kiromic BioPharma, Inc. (NASDAQ:KRBP)
Portage Biotech Acquires Tarus Therapeutics In Exchange For 2,425,999 PRTG Shares Along With Assumption Of $3M In Liabilities; Additionally, Payments Of Up To $32M Would Be Triggered Upon Achievement Of Future Milestones
Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration
Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at
Saratoga Investment Q1 EPS $0.53, Inline
Saratoga Investment (NYSE:SAR) reported quarterly earnings of $0.53 per share which met the analyst consensus estimate. This is a 5.36 percent decrease over earnings of $0.56 per share from the same period last year.
Simulations Plus Q3 EPS $0.20 Beats $0.17 Estimate, Sales $15.00M Beat $14.33M Estimate
Simulations Plus (NASDAQ:SLP) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 11.11 percent increase over earnings of $0.18 per share from the
Calithera Biosciences Announces First Patient Enrolled In Phase 2 Clinical Trial Of Sapanisertib In Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in